Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 451Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Triple Negative Breast Neoplasms 162Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 141Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 74Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Small Cell Lung Carcinoma 39Glioblastoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Lymphoma 34

Interventions

Etoposide 3Carboplatin 3Paclitaxel 2sintilimab 1pembrolizumab 1olaparib 1ceralasertib 1atezolizumab 1apatinib 1anlotinib 1Topotecan 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × SCLC × pembrolizumab × Clear all
NCT04677361 2021-10-08

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

Fox Chase Cancer Center

Phase EARLY_PHASE1 Withdrawn
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡